Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Aligos Therapeutics

Aligos Therapeutics Presents Clinical Data from NASH Program at the 2023 Paris Hepatology Conference
From Aligos Therapeutics
Via Globe NewsWire
Tickers ALGS
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results
From Aligos Therapeutics
Via Globe NewsWire
Tickers ALGS
Aligos Therapeutics to Announce Fourth Quarter Results March 9, 2023
From Aligos Therapeutics
Via Globe NewsWire
Tickers ALGS
Aligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver
From Aligos Therapeutics
Via Globe NewsWire
Tickers ALGS
Aligos Therapeutics to Present Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver
From Aligos Therapeutics
Via Globe NewsWire
Tickers ALGS
Aligos Therapeutics to Present at the SVB Securities Global Biopharma Conference
From Aligos Therapeutics
Via Globe NewsWire
Tickers ALGS
Aligos Therapeutics Announces Strategic Reprioritization of NASH and COVID-19 Programs and Confirms Key Timelines and Extension of Cash Runway to Year-End 2024
From Aligos Therapeutics
Via Globe NewsWire
Tickers ALGS
Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009
From Aligos Therapeutics
Via Globe NewsWire
Tickers ALGS
Aligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB)
From Aligos Therapeutics
Via Globe NewsWire
Tickers ALGS
Aligos Therapeutics Presents Nonclinical Data for its Coronavirus Therapeutic Program at the 2022 Respi DART Meeting
From Aligos Therapeutics
Via Globe NewsWire
Tickers ALGS
Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD’s The Liver Meeting® 2022
From Aligos Therapeutics
Via Globe NewsWire
Tickers ALGS
Aligos Therapeutics Presents Clinical Data for its Capsid Assembly Modulator, ALG-000184, at AASLD’s The Liver Meeting® 2022
From Aligos Therapeutics
Via Globe NewsWire
Tickers ALGS
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results
From Aligos Therapeutics
Via Globe NewsWire
Tickers ALGS
Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD’s The Liver Meeting® 2022
From Aligos Therapeutics
Via Globe NewsWire
Tickers ALGS
Aligos Therapeutics to Announce Third Quarter Results November 2, 2022
From Aligos Therapeutics
Via Globe NewsWire
Tickers ALGS
Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA
From Aligos Therapeutics
Via Globe NewsWire
Tickers ALGS
Aligos Therapeutics Initiates Dosing In Healthy Volunteers With siRNA Drug Candidate ALG-125755
From Aligos Therapeutics
Via Globe NewsWire
Tickers ALGS
Aligos Therapeutics Files Response to Janssen Biopharma Lawsuit and Lodges Counterclaims Alleging Unfair Competition and Promissory Fraud
From Aligos Therapeutics
Via Globe NewsWire
Tickers ALGS
Aligos Therapeutics to Announce Second Quarter 2022 Results August 4, 2022
From Aligos Therapeutics
Via Globe NewsWire
Tickers ALGS
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.